Search results
Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 2 years agoFulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript February 27, 2024 Fulcrum...
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 1 year agoFulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 12.77% and 82.95%,...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) institutional owners may be pleased with recent gains after...
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights Significantly high institutional ownership implies Fulcrum Therapeutics' stock price is...
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Simply Wall St. via Yahoo Finance· 3 weeks agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
Investors in Fulcrum Therapeutics (NASDAQ:FULC) have unfortunately lost 45% over the last year
Simply Wall St. via Yahoo Finance· 10 months agoFulcrum Therapeutics, Inc. (NASDAQ:FULC) shareholders should be happy to see the share price up 18%...
Is Fulcrum Therapeutics (NASDAQ:FULC) In A Good Position To Invest In Growth?
Simply Wall St. via Yahoo Finance· 1 year agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Strength Seen in Fulcrum Therapeutics, Inc. (FULC): Can Its 20.6% Jump Turn into More Strength?
Zacks via Yahoo Finance· 1 year agoFulcrum Therapeutics, Inc. (FULC) witnessed a jump in share price last session on above-average...
Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights
GuruFocus.com via Yahoo Finance· 7 months agoFulcrum Therapeutics Inc (NASDAQ:FULC) reported a net loss of $24.0 million for Q3 2023, compared to...
CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock
Simply Wall St. via Yahoo Finance· 3 months agoInvestors who take an interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) should definitely note...